Right on Rick-man! Management didn't build a warehouse and put millions of personal gain at stake only to see it go down in flames - they know what Ampion can do - and soon the rest of the world will know too. Bar-Orr could be making millions elsewhere if he didn't believe in AMPE's pipeline.
P.S. - Life is so peaceful on this board when you put ri66 on IGNORE.
Flexion patient dosing underway in lead product study • 4:27 PM
Douglas W. House, SA News Ed...
The first patient has been dosed in a 450-patient Phase 3 clinical trial assessing Flexion Therapeutics' (NASDAQ:FLXN) lead product candidate, FX006, for the treatment of moderate-to-severe pain associated with osteoarthritis of the knee.
FX006 is a novel, non-opioid, sustained release, intra-articular formulation of triamcinolone acetonide. The company expects top line data in 2016.
The FDA lifted its clinical hold on the company's Phase 2b trial in early December after it concluded its investigation of a case of septic shock in one patient.